Development of Cannabinoids for Clinical Use - CNS Hazards and Therapeutic Effects
Tuesday April 07, 2020
8:00 am
-
10:00 am
Eastern Time (ET)
Room 16 B
BEH
DDD
NEU
TCP
Chair :
Marcus Delatte
Food and Drug Administration
Ziva Cooper
UCLA Cannabis Research Initiative
The development of potential therapeutic products such as cannabinoids is a complex process that requires the integration of various types of data to understand the potential therapeutic and toxic effects of products in humans. This symposium will review the regulatory expectations of the FDA for the quality of cannabinoid-containing products that are either botanicals or highly purified drug products; discuss the antinociceptive and adverse effects of cannabinoids in animals and leverage these results to inform the design of clinical protocols; as well as review the analgesic and adverse effects of cannabinoids in humans.
Speakers
Brenda Gannon
- Steep Hill Arkansas
Cannabinoids: Product Quality Information and Regulatory Expectations
Peter Winsauer
- Louisiana State University Health Sciences Center
Effects of Cannabinoids on Complex Behaviors and Antinociception in Animals
Marcus Delatte
- Food and Drug Administration
Cannabinoids: Hazard Assessment and Management Based on Nonclinical Data
Ziva Cooper
- UCLA Cannabis Research Initiative
Cannabinoids in the Clinic: Considering Abuse Liability when Evaluating Analgesic Effects